NCX 470 for Glaucoma
(Whistler Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new eye drop called NCX 470, a nitric oxide-donating bimatoprost prostaglandin analog, to assess its effect on the liquid in the eye, which influences eye pressure. The study compares NCX 470 with a placebo to better understand its impact. It targets individuals without glaucoma who may have high eye pressure. Those with higher-than-normal eye pressure but without glaucoma or other serious eye issues might be suitable for this trial. As a Phase 2/3 trial, this research measures the treatment's effectiveness in an initial, smaller group and represents the final step before FDA approval, offering participants a chance to contribute to advancing eye care.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that NCX 470 is likely to be safe for humans?
Research has shown that NCX 470, an eye drop that releases nitric oxide, is generally safe for patients. Studies have found it effectively reduces high eye pressure in individuals with open-angle glaucoma or ocular hypertension. Importantly, these studies did not identify any new safety concerns with its use.
In trials, researchers compared NCX 470 to latanoprost, a common glaucoma medication. Results indicated that NCX 470 not only matched but also outperformed latanoprost in lowering eye pressure. Additionally, no new safety issues emerged with NCX 470 over time. This suggests that the treatment is generally safe based on current evidence.12345Why do researchers think this study treatment might be promising?
Most treatments for glaucoma work by reducing eye pressure, often using drugs like prostaglandin analogs or beta-blockers. But NCX 470 takes a different approach, combining a nitric oxide-donating prostaglandin analog. This combination not only reduces intraocular pressure but also enhances blood flow to the optic nerve, which could protect against glaucoma damage. Researchers are excited about its potential to work faster and more effectively than standard treatments, possibly showing results in just a few days with once-daily dosing.
What evidence suggests that NCX 470 might be an effective treatment for glaucoma?
Research has shown that NCX 470 effectively lowers eye pressure, crucial for treating conditions like glaucoma. In studies, NCX 470 0.1% reduced eye pressure more effectively than latanoprost, a common treatment, achieving reductions of 7.9 to 10.0 mmHg compared to 7.1 to 9.8 mmHg with latanoprost. This trial will test NCX 470 0.1% against a placebo to further evaluate its effectiveness and safety. Additionally, patients tolerated it well, which is important for long-term use. Overall, these findings suggest that NCX 470 could be a promising option for managing high eye pressure and open-angle glaucoma.12346
Are You a Good Fit for This Trial?
This trial is for adults over 18 years old, of any gender, who do not have glaucoma but may have ocular hypertension (OHT) with eye pressure between 16 and 28 mmHg. It's not suitable for people already diagnosed with glaucoma.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive NCX 470 0.1% or placebo, one drop in the randomized eye once a day for 8 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NCX 470
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nicox Ophthalmics, Inc.
Lead Sponsor